2 trial was 0.59 (95% CI 0.15-0.82). Conclusion: Despite an apparent correlation between CRB and major bleeding in major orthopedic surgery, AF, and double-blind acute VTE studies, the wide CIs suggest that CRB might not be an acceptable surrogate outcome in any of these settings.
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Essentials
• Surrogacy of clinically relevant bleeding (CRB) for major bleeding has never been validated.
• Our meta-analysis evaluated CRB surrogacy in trials of new versus traditional anticoagulants.
• Surrogacy was not validated in orthopedic surgery, venous thromboembolism or atrial fibrillation • The difficulty in demonstrating the surrogacy may reflect a lack of homogeneity in its definition Summary. Background: Clinically relevant bleeding (CRB), comprising major bleeding and clinically relevant nonmajor bleeding, has been used as a surrogate for major bleeding in most anticoagulant trials. The validity of this surrogate to estimate trade-off between thrombotic and bleeding events in clinical trials was never assessed. Methods: We systematically reviewed randomized phase III trials comparing new anticoagulants with the standard of care for venous thromboembolism prevention following major orthopedic surgery, venous thromboembolism (VTE) treatment, or stroke and systemic embolism prevention in atrial fibrillation (AF), and reporting both major bleeding and CRB rates. The validity of CRB as a surrogate for major bleeding was assessed according to the strength of the association between the relative risks of major bleeding and CRB, measured by the use of R 2 trial and its 95% confidence interval (CI). Results: In the postoperative prophylactic setting (13 studies), major bleeding and CRB rates were 1.12% and 3.56%, respectively, and R 2 trial was 0.69 (95% CI 0.34-0.93). For acute VTE studies (n = 12), major bleeding and CRB rates were 1.87% and 9.07%; the corresponding R 2 trial values were 0.28 (95% CI 0.01-0.80) and 0.68 (95% CI 0.09-1.00) when only double-blind studies were considered (n = 7). For AF studies (n = 7; 22 strata), major bleeding and CRB rates were 4.82% and 15.3%, and R
Introduction
In recent years, various new anticoagulants, including direct oral anticoagulants (DOACs), have been compared with the traditional anticoagulant regimen based on low molecular weight heparin, with or without a vitamin K antagonist, for the prophylaxis and treatment of venous thromboembolism (VTE) or the prevention of embolic complications in patients with atrial fibrillation (AF). The advantages of DOACs over the traditional prophylactic and therapeutic regimens include their oral administration and the absence of any need for monitoring. Accordingly, the majority of trials assessing DOACs have been conducted and powered to demonstrate at least non-inferiority on efficacy. In contrast, owing to the very low rate of major bleeding observed with the reference treatment, these studies were underpowered to show any statistically significant results on that outcome.
For optimal assessment of the benefit-to-risk ratio, the trial sample size should be computed on the basis of the lowest rate of events between the primary efficacy outcome and major bleeding. However, this may be prohibitively expensive and also more difficult to achieve in terms of both the feasibility of recruitment and the time required for study completion.
Clinically relevant bleeding (CRB) was first proposed in 2003 as a warning sign and surrogate outcome for major bleeding, the true outcome, i.e. that representing a substantial healthcare burden [1] . CRB includes both major bleeding and clinically relevant non-major bleeding (CRNMB), defined as any bleeding not meeting the criteria for major bleeding but associated with a need for medical intervention [2] . The incidence of CRB was at least 3% in most recent studies in major orthopedic surgery [3] [4] [5] , and approximately 8-12% in studies concerning the acute treatment of VTE and the prevention of stroke and systemic embolism in AF [6, 7] , as compared with 1.5%, 1.5%, and 2.5%, respectively, for major bleeding [2, [8] [9] [10] [11] [12] . The use of a surrogate may also be the sole possibility in phase II studies performed to determine the optimal dose for efficacy and safety. In these studies with small sample sizes, the choice of major bleeding as the main safety outcome does not allow discrimination of the optimal treatment doses.
To assess the validity of a surrogate outcome, a correlation between the effect size for the surrogate and that for the clinically most important outcomes must be demonstrated, as a surrogate outcome is expected to predict clinical benefit. This step has never been performed for bleeding outcomes. Several methods for validating surrogate outcomes have been developed, including metaanalytic approaches based both on the strength of the correlation between the treatment effect on the surrogate outcome and that on the true outcome [13] [14] [15] [16] , and on the strength of evidence, as recommended [17] . We performed a meta-analysis of published randomized controlled trials in three indications (prevention of VTE in major orthopedic surgery, acute treatment of VTE, and prevention of stroke or systemic embolism in AF) to evaluate CRB as a surrogate outcome for major bleeding.
Materials and methods

Literature search and study identification
We sought to identify all relevant published and unpublished randomized controlled trials assessing the efficacy and safety of new oral anticoagulants as compared with the reference treatment in the prevention of VTE in major orthopedic surgery, the treatment of VTE (deep vein thrombosis and pulmonary embolism), and the prevention of stroke and systemic embolism in AF. All studies had to report both major bleeding and CRB as safety outcomes.
An exhaustive literature search, both manual and computer-assisted, was performed from the first use of CRB criteria (2003) to May 2016, with no restrictions on language or dates. The computer-assisted search was carried out on electronic databases (MEDLINE, the Cochrane Library databases, SCOPUS, Google Scholar, and the international database of clinical trials [www.clinicaltria ls.gov]). In addition, conference proceedings from the ISTH, International Congress of Thrombosis, European Society of Cardiology, American Heart Association and American Society of Hematology were searched for abstracts of relevant trials. The following keywords were used: apixaban, rivaroxaban, betrixaban, fondaparinux, dabigatran etexilate, idrabiotaparinux, idraparinux, AZD0837, edoxaban, semuloparin, randomized, randomized controlled trial, venous thrombosis, venous thromboembolism, VTE, deep vein thrombosis, DVT, pulmonary embolism, PE, atrial fibrillation, prophylaxis, orthopedic surgery, hip fracture, hip/knee surgery, hip/ knee replacement, hip/knee arthroplasty, and acute treatment. We also manually searched the reference lists of journal articles reporting results from clinical trials, metaanalyses, and systematic reviews, to find additional studies. When studies had been published as both an abstract and a full article, only the article was referenced. If more than one article was published for the same study, we extracted the relevant information from all publications as needed.
Study selection
Two of the authors (S.L. and C.C.) independently assessed studies for possible inclusion, using the following predefined criteria. Studies had to be randomized controlled trials, evaluating an anticoagulant as compared with an active control in the prevention of VTE after major orthopedic surgery, in the treatment of VTE, or in the prevention of stroke and systemic embolism in AF, and reporting as outcomes CRB events (major bleeding and CRNMB) and major bleeding. Disagreements were resolved by consensus, including the opinion of a third assessor (L.B.).
Outcomes
The definition of major bleeding was considered according to the indication. In surgical patients, we used, whenever available, the European Agency for the Evaluation of Medical Products definition [18] , i.e. the composite of fatal bleeding, bleeding occurring in a critical organ, bleeding warranting treatment cessation, bleeding located at the surgical site and leading to reoperation, or clinically overt bleeding associated with a decrease in hemoglobin level of ≥ 20 g L À1 as compared with baseline or leading to transfusion of ≥ 2 units of whole blood or packed red blood cells. In non-surgical patients, we used the ISTH definition [19] , i.e. the composite of fatal bleeding, bleeding occurring in a critical organ, or clinically overt bleeding associated with a decrease in hemoglobin level of ≥ 20 g L À1 as compared with baseline or leading to transfusion of ≥ 2 units of whole blood or packed red blood cells. CRNMB was usually defined as bleeding episodes that were clinically relevant but did not qualify as major (e.g. epistaxis that required interventions, the formation of a large hematoma visible on the skin, or spontaneous macroscopic hematuria) [1] . CRB included both major bleeding and CRNMB.
Quality assessment and data extraction
The methodological quality of each trial was evaluated with the Cochrane Collaboration tool for assessing risk of bias in randomized trials [20] . When a trial was deemed to be eligible, predefined trial data were extracted independently by two of the authors (S.L. and C.C.). The following data were extracted: name of the first author and study acronym, year(s) of publication, number of randomized patients, number of patients included in the safety population, study design (open-label; prospective, randomized, open blinded-endpoint [PROBE]; double-blind), study quality, indication, treatment regimens (drug dose and treatment duration), and safety endpoints: major bleeding and CRB during study treatment. In the event of discrepancies in either study selection or data extraction, agreement was reached in a concordance meeting.
Statistical analysis
Overall rates of CRB and major bleeding were calculated in the control group by indication, and weighted according to the size of the study. For each indication, we computed the ratio of the rate of CRB to that of major bleeding to express the relative magnitudes of CRB and major bleeding frequency. To compute a single ratio for each study, rates in the control group were computed, and the CRB rate was divided by the corresponding major bleeding rate [21] .
Forest plots were used to display the relative risk (RR) overall and for individual trials. The RRs compared the risk in patients treated with the new anticoagulant regimen with that in patients treated with the reference regimen, and were calculated for both outcomes: the true outcome (major bleeding) and the surrogate outcome (CRB). Relative risks and corresponding 95% confidence intervals (CIs) are presented. All analyses were performed on an intention-to-treat (ITT) basis.
We used the approach proposed by Buyse et al., considering the study as the statistical unit [13] . In this approach, the validity of a surrogate is determined by the precision with which a trial-specific treatment effect on the true outcome can be predicted from the effect on the surrogate. The correlation of the two effects is calculated by use of a linear regression model based on trial-specific treatment effects on the true and surrogate outcomes, i.e. on the association between the logarithm of the RR for CRB and that for major bleeding, weighted according to the size of trials. Whenever available, without a non-zero cell, the results obtained for individual strata (mainly derived from a unique by-subgroup analysis giving results for the two types of bleeding) were used rather than the overall result of the study, to increase the number of statistical units and allow a more precise estimate of the regression.
The strength of the association was assessed by use of the coefficient of correlation R trial and the coefficient of determination R 2 trial . The 95% CIs for R 2 trial and the weighted fit were calculated with the percentile bootstrapping method (resampling 1000 times). The correlation was assessed by indication: prevention of VTE in major orthopedic surgery, treatment of VTE, and prevention of stroke in AF. In accordance with current guidelines, proof of the validity of the surrogate was inferred from a strong correlation, defined as a lower limit of the 95% CI of R 2 trial of > 0.72 [14] . A weak correlation (upper limit of the 95% CI of the R 2 trial of ≤ 0.5) was considered to denote non-validity of the surrogate [17] . We assume that the surrogate and true endpoints are jointly normally distributed and are able to compute the 95% prediction interval of the linear regression. The 95% prediction limits indicate the range of effects on major bleeding that can be expected for a given effect on CRB. The surrogate threshold effect (STE) is the value of the treatment effect on the surrogate for which the 95% prediction interval of the corresponding effect on the true endpoint excludes an effect of 0. The validity of CRB as a surrogate was also assessed by determining whether the treatment effect on this surrogate outcome reliably predicted the treatment effect on the true outcome (major bleeding) according to the STE [15] [16] [17] . The STE is defined as the minimum treatment effect on the surrogate that is necessary to predict a non-zero effect on the true outcome: in a future trial using treatment modalities, similar to those in the set of trials included in the meta-analysis, an RR of CRB greater than the STE would predict an RR of major bleeding of > 1. From a clinical point of view, a large STE value would point to the need for observing a large treatment effect on the surrogate endpoint to conclude that there is a non-zero effect on the true endpoint.
For each of the three indications, two sensitivity analyses were planned to further establish the robustness of the results: the first analysis being conducted on the safety population rather than the ITT population, and the second one including only double-blind studies.
Meta-analysis of the use of new anticoagulants as compared with the reference treatment, forest plots for each endpoint and calculation of the weighted linear regression were accomplished with R statistical software, version 3.3.1 with the META, NLME and GGPLOT packages.
Results
Study selection
Our search identified 283 articles of interest, of which 195 were excluded after abstract review and 60 after full-text review (Fig. 1) . Finally, 29 articles, reporting 32 randomized studies (in 146 018 patients), were considered to be eligible for data extraction. These studies are described in Table 1 . The full references for the studies are provided in Data S1.
Study description
Most of the studies were double-blind (26 studies, 125 828 patients), six studies being open with blind adjudication (PROBE design, 20 190 patients). The risk of bias according to the Cochrane Collaboration tool is shown in Table 2 . Most of the studies were at low risk of bias for each item of the tool, indicating a strong methodological design. Funnel plots for both major bleeding and CRB revealed no evidence of publication bias, given that there was no pattern of non-significant results being under-reported, even at low sample sizes (Egger test for major bleeding, P = 0.60; Egger test for CRB, P = 0.37; data not shown).
Thirteen studies focused on patients undergoing major orthopedic surgery (36 622 patients), 12 studies on patients with acute VTE (40 598 patients), and seven studies on patients with AF (68 798 patients). Treatment duration varied from 7 days to 38 days in patients undergoing major orthopedic surgery, and from 5 days to 12 months in the acute treatment of VTE. In patients with AF, treatment duration was available for only one study. The RRs for individual trials for both major bleeding and CRB are shown for each indication in Fig. S1 . The results of the meta-analysis are shown by clinical setting in Fig. 2 . In major orthopedic surgery, the overall rates for major bleeding and CRB were 1.12% (95% CI 0.96-1.27%) and 3.56% (95% CI 3.28-3.84%), respectively. The median ratio between CRB and major bleeding rates across trials was 2.75 (from 1.33 to 7.44). In acute VTE, the overall rates of major bleeding and CRB were 1.87% (95% CI 1.68-2.05%) and 9.07% (95% CI 8.67-9.46%), respectively. The median ratio between CRB and major bleeding ratesacross trials was 4.63 (from to 1.93 to 6.90). For the studies in AF, the rates of major bleeding and CRB were 4.82% (95% CI 4.58-4.06%) and 15.3% (95% CI 14.8-15.6%), respectively. The median ratio between CRB and major bleeding across trials was 3.56 (from 1.90 to 8.10). Whatever the clinical setting, the meta-analysis results for CRB were apparently close to those for major bleeding (Fig. 2) . A significant treatment effect on bleeding was observed in studies focusing on acute treatment of VTE, whereas no such effect was seen in the two other clinical settings.
Surrogacy of CRB in major orthopedic surgery
Correlations between anticoagulant treatment effects on CRB and major bleeding for the 13 studies performed in major orthopedic surgery are shown in Fig. 3 . The coefficient of determination for the estimated treatment effects, R 2 trial , was 0.69 (95% CI 0.34-0.93). The corresponding linear regression model was log RR(major bleeding) = 1. 29 (standard error [SE] 0.23) 9 log RR (CRB) -0.11 (SE 0.08). The moderate correlation at the trial level is reflected by an STE equal to 2.05, which we can interpret as follows: a minimal effect on CRB corresponding to an RR of 2.05 may be considered as a safety warning predicting a non-zero effect on major bleeding. In other words, we need to observe an RR of CRB of at least 2.05 to be able to observe an RR of major bleeding of > 1.
When the analysis was performed on the safety population, the results remained the same (data not shown). As the studies included in this indication were all doubleblind, it was not possible to assess the impact of study design.
Surrogacy of CRB in the treatment of acute VTE
Correlations between anticoagulant treatment effects on CRB and major bleeding for the 12 studies concerning the treatment of VTE are shown in Fig. 4 . The coefficient of determination, R 2 trial , for the estimated treatment effects was 0.28 (95% CI 0.01-0.80). The linear regression model was log RR(major bleeding) =0.83 (SE 0.37) 9 log RR (CRB) -0.22 (SE 0.15). When the analysis was performed on the safety population, the results remained unchanged (data not shown). When only double-blind studies were considered, the coefficient of determination was better, despite wide CIs: R 2 trial = 0.68 (95% CI 0.09-1.00). In terms of safety as a whole, the STE that would predict a non-zero effect could not be estimated.
Surrogacy of CRB in AF
Correlations between CRB and major bleeding for the seven studies (22 strata) in AF are shown in Fig. 5 . The coefficient of determination, R 2 trial , for the estimated treatment effects between CRB and major bleeding was 0.59 (95% CI 0.15-0.82). The linear regression model was log RR(major bleeding) = 1.14 (SE 0.21) 9 log RR (CRB) -0.04 (SE 0.07). The results remained unchanged when the analysis was performed on the safety population (data not shown). When only double-blind studies were included, the coefficient of determination, R 2 trial , was 0.36 (95% CI 0.05-0.72). In terms of safety, a minimal effect on CRB equal to 2.33 would predict an RR of major bleeding of > 1.
Surrogacy of CRB in all indications
When the data for all indications were pooled for analysis of the association between CRB and major bleeding, .35-0.75) . In terms of safety, a minimal effect on CRB equal to 2.15 would predict an RR of major bleeding of > 1.
Discussion
The objective of this study was to validate, by a comprehensive meta-analysis of 32 studies, the value of CRB as a surrogate outcome for major bleeding, taking into account the greater frequency of CRB than of the true outcome, major bleeding. As a proxy for the true outcome, a surrogate should fulfill several criteria considered in this analysis of CRB [22] [23] [24] [25] [26] .
First, CRB is an outcome that is easily measurable and more frequent than major bleeding as evaluated by an independent central adjudication committee. The median ratio across trials between CRB and major bleeding was 2.75 in major orthopedic surgery, 4.63 in acute VTE, and 3.56 in AF; that is, CRB was approximately three-fold more frequent in all indications.
Second, even though CRB and major bleeding are apparently correlated, this is not sufficient. Ultimately, one would also need to know that a change in the surrogate outcome necessarily elicits changes in the true outcome, i.e. that the treatment effects are correlated. In major orthopedic surgery, double-blind trials in acute treatment of VTE, and AF, the lower limit of the CI of correlations observed between the treatment effect on major bleeding and that on CRB (0.34, 0.09 and 0.35, respectively) were below the threshold strength of evidence set by guidelines, which is generally > 0.60. Although the threshold was proposed in the field of oncology, it was mainly derived from an expected strength of association, and was then applicable to other clinical conditions. Finally, whatever the clinical situation, as extensively discussed by Ciani et al., further work is needed to obtain a consensus as to what constitutes an acceptable level of correlation to establish the validity of surrogate endpoints [27, 28] .
Third, particularly in cases in which no strong correlation is evident, i.e. the validity of the surrogate outcome remains unclear, conclusions about patient-relevant endpoints can still be made by applying the STE concept [15] . This approach can be valuable if a sufficiently large treatment effect on the surrogate outcome has been shown, this being true only in the setting of acute VTE in our study (Fig. 2) . The STE concept allows specification of threshold values for deciding whether an observed effect on the surrogate outcome is accompanied by an effect on the endpoint of interest. To draw such a conclusion, the lower limit of the CI of the treatment effect on the surrogate must be greater than the STE, as is the case for CRB in the acute VTE setting.
Overall, for the three types of study combined, the STE was 2.15 for detection of a safety issue associated with an anticoagulant treatment in terms of major bleeding. In Trial-level association between treatment effects on clinically relevant bleeding (CRB) and major bleeding (MB) in the prevention of venous thromboembolism after major orthopedic surgery. Each study is represented by a bubble, the size of the bubble being proportional to the size of the study. A log scale was used for the x-axis and y-axis. The solid dark line represents the regression line, and the dashed dark lines the 95% prediction interval. The surrogate threshold effect is 2.05. RR, relative risk.
other words, we need to observe an RR of CRB of at least 2.15 to be able to observe an RR of major bleeding of > 1.
The validity of surrogate efficacy outcomes has been evaluated with a similar correlation approach in oncology [29] [30] [31] [32] and prevention of VTE [33] . However, whereas attention has been paid to the evaluation and validation of surrogates for efficacy outcomes, the use of surrogates for safety outcomes has not been studied. It is well known that there is no possible surrogate for unexpected safety effects [34] . However, surrogate for safety is relevant for common and expected safety outcomes because directly link with the mechanism of action of the evaluated treatments. This applies especially to the use of CRB as a surrogate for major bleeding. One problem related to this approach is the difficulty in interpreting the R 2 trial value. Obviously, an R 2 trial of 1 would be desirable, as this would imply a perfect prediction, but such a scenario is not encountered in practice. However, when R 2 trial differs from 1, it is not clear what value would be sufficient to for the surrogate valid to be deemed valid. In this meta-analysis, even considering that 60% of the treatment effect on the true outcome could be predicted by the effect on the surrogate outcome in major orthopedic surgery, AF, and VTE (when only double-blind VTE trials were considered), this result remains imprecise and suffers from a lack of statistical power, especially in relation to the meta-analysis method. With this approach, the statistical unit of the correlation is the study, and the number of units is small. The use of results concerning individual strata, based on study center, for example, allows a more precise estimation of the regression, but individual patient data or stratified data are needed for such approach [35] .
Apparently inadequate surrogacy may also reflect a lack of homogeneity in definition of the surrogate outcome. This problem, in particular lack of objectivity, could apply to CRB, and might explain the better correlation observed with double-blind studies in the setting of acute VTE treatment. An ISTH working group recently published a definition for CRNMB in non-surgical patients, which, together with the ISTH definition of major bleeding, allows definition of CRB in this context [2] . A consensual definition of CRB is still needed in the surgical setting.
We were not able to demonstrate that CRB could be an acceptable surrogate outcome for major bleeding in major orthopedic surgery, acute treatment of VTE, and AF. At present, CRB appears to be simply a measure of drug safety, and not a surrogate for major bleeding. Addendum S. Laporte was the chair of the working group META-EMBOL, and designed the study. M. Cucherat designed the study. C. Chapelle, J.-C Lega, and E. Ollier performed the extraction of the data and the statistical analysis using R software. L. Bertoletti, P. Zufferey, A. Merah, H. D ecousus, S. Schulman, G. Meyer, and P. Mismetti as members of steering or adjudication committees in current or past randomized controlled trials in this field, supervised the practical organization of the study and the definition of the criteria used. S. Laporte and C. Chapelle drafted the main manuscript, with contributions from all other authors. All authors approved the final version.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Data S1. Full study references. Fig. S1 . Forest plot of relative risks (RRs) for major bleeding (true outcome) and clinically relevant bleeding (surrogate outcome).
